CTXR logo

CTXR
Citius Pharmaceuticals Inc

21,518
Mkt Cap
$21.53M
Volume
664,047.00
52W High
$2.48
52W Low
$0.63
PE Ratio
-0.33
CTXR Fundamentals
Price
$0.8806
Prev Close
$0.9622
Open
$0.96
50D MA
$0.8154
Beta
1.42
Avg. Volume
531,043.58
EPS (Annual)
-$3.38
P/B
0.27
Rev/Employee
$0.00
$21.26
Loading...
Loading...
News
all
press releases
Citius Oncology Announces Positive Topline Results from InvestigatorInitiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
Citius Oncology Announces Positive Topline Results from InvestigatorInitiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers Citius Oncology...
PR Newswire·7d ago
News Placeholder
More News
News Placeholder
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR (E7777) Dosing Prior to Commercial CART Therapy in HighRisk Diffuse Large BCell Lymphoma
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR (E7777) Dosing Prior to Commercial CART Therapy in HighRisk Diffuse Large BCell Lymphoma Citius Oncology Announces...
PR Newswire·13d ago
News Placeholder
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program PR...
PR Newswire·21d ago
News Placeholder
Citius Pharmaceuticals Q1 Earnings Report: What Investors Need to Know
read more...
Benzinga·1mo ago
News Placeholder
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of...
PR Newswire·1mo ago
News Placeholder
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR PR Newswire...
PR Newswire·1mo ago
News Placeholder
Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar
Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar Citius Oncology Expands International Distribution of LYMPHIR to European...
PR Newswire·1mo ago
News Placeholder
Citius Pharmaceuticals (CTXR) Surges 22% After Hours Here's Why
Citius Pharmaceuticals shares jumped 22.12% after hours following the commercial launch of its LYMPHIR therapy and a fiscal 2025 business update.read more...
Benzinga·3mo ago
News Placeholder
Citius Pharmaceuticals Inc. Full Year Loss Decreases
(RTTNews) - Citius Pharmaceuticals Inc. (CTXR.OB) released Loss for full year of -$37.43 million...
Nasdaq News: Markets·3mo ago
News Placeholder
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business...
PR Newswire·3mo ago
<
1
2
...
>

Latest CTXR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.